hospital-acquired pneumonia/ventilator-associated pneumonia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with unlimited gender and weight, aged >= 65 years; 2. HAP / VAP patients confirmed or proposed to be caused by cro infection by clinical symptoms, physical signs, laboratory examination and pathogenic microorganism examination; 3. The patients who need to use polymyxin B and monitor the concentration of polymyxin B treatment drugs due to clinical needs; 4. Polymyxin B combined with other antimicrobial agents are also included in the group, such as ß - lactams, carbapenems, fluoroquinolones and other drugs for the treatment of drug-resistant gram-negative bacilli or combination of drug-resistant Gram-positive bacilli; 5. Patients who understand and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients allergic to polymyxin B; 2. Patients with gram-negative bacilli as colonizing bacteria without infection basis; 3. Patients who lack of clinical infection and laboratory evaluation indexes and cannot be evaluated for efficacy and safety; 4. Patients (such as vancomycin, aminoglycoside, etc.) who use nephrotoxic drugs within 3 days before starting the treatment of polymyxin B and who are combined or expected to use nephrotoxic drugs during the study period; 5. Patients with a course of polymyxin B less than 5 days (except hemodialysis and peritoneal dialysis patients); 6. Patients who participated in other clinical studies within the previous 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathogenic bacterium;blood concentration;mortality;mortality;AE rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic data;Vital signs;underlying disease;Concurrent drug;blood routine examination;Biochemical indexes;urine routine examination;C-Reactive Protein;procalcitonin;endotoxin; | — |
Countries
China
Contacts
Huadong Hospital affiliated to Fudan University